What Prevail Therapeutics Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Orbimed Advisors Llc | Director | Jan 22 | Tender Offer · U | −13,822,463 | — | — | 0 |
| Nussbaum Ran | Director | Jan 22 | Tender Offer · U | −1,576,881 | — | — | 0 |
| Gordon Carl L | Director | Jan 22 | Tender Offer · U | −13,822,463 | — | — | 0 |
| Nader Francois | Director | Jan 22 | Tender Offer · U | −23,747 | — | — | 0 |
| Thompson Peter A. | Director | Jan 22 | Tender Offer · U | −13,822,463 | — | — | 0 |
| Tyto Acquisition Corp | 10% owner | Jan 22 | Open-market buy · P | +34,284,789 | $22.50 | +$771M | 100 |
| Abeliovich Asa | President & CEO | Jan 22 | Tender Offer · U | −2,385,756 | — | — | 0 |
| Minkow Emily | Chief Business Officer | Jan 22 | Tender Offer · U | −13,000 | — | — | 0 |
| Abeliovich Asa | President & CEO | Dec 30 | Withheld — tax / exercise cost · F | −89,037 | $23.02 | −$2.05M | 2,385,756 |
| Abeliovich Asa | President & CEO | Dec 30 | Exercise / conversion · M | +120,537 | $10.26 | +$1.24M | 2,474,793 |
| Abeliovich Asa | President & CEO | Dec 30 | Exercise / conversion · M | +5,256 | $0.18 | +$946 | 2,354,256 |
| Minkow Emily | Chief Business Officer | Dec 24 | Exercise / conversion · M | +13,000 | $0.18 | +$2.34K | 13,000 |
| Thompson Peter A. | Director | Jun 24 | Open-market buy · P | +882,352 | $17.00 | +$15M | 13,822,463 |
| Thompson Peter A. | Director | Jun 24 | Derivative Conversion · C | +10,510,111 | — | — | 12,940,111 |
| Orbimed Advisors Llc | Director | Jun 24 | Open-market buy · P | +882,352 | $17.00 | +$15M | 13,822,463 |
| Orbimed Advisors Llc | Director | Jun 24 | Derivative Conversion · C | +10,510,111 | — | — | 12,940,111 |
| Gordon Carl L | Director | Jun 24 | Open-market buy · P | +882,352 | $17.00 | +$15M | 13,822,463 |
| Gordon Carl L | Director | Jun 24 | Derivative Conversion · C | +10,510,111 | — | — | 12,940,111 |
| Nader Francois | Director | Jun 24 | Derivative Conversion · C | +23,747 | — | — | 23,747 |
Loading...
